Drinabant

Summary

Drinabant (CHEMBL3545166) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 497.4 Da · C23H20Cl2F2N2O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545166
Name	Drinabant
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	10278470
Molecular formula	C23H20Cl2F2N2O2S
Molecular weight	497.4
InChIKey	IQQBRKLVEALROM-UHFFFAOYSA-N

SMILES: CS(=O)(=O)N(C1CN(C1)C(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)C4=CC(=CC(=C4)F)F

IUPAC name: N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-N-(3,5-difluorophenyl)methanesulfonamide

Also known as: Ave1625, Drinabant, DRINABANT

Patent coverage: 151 distinct patent families (375 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
Alzheimer disease	1	MONDO:0004975	MONDO:0004975

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00380302	PHASE1/PHASE2	COMPLETED	Activity of AVE1625 in Mild to Moderate Alzheimer’s Patients.
NCT00439634	PHASE2	TERMINATED	Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).